Tesamorelin, Ipamorelin (Blend)

Ipamorelin, the first selective growth hormone secretagogue — European Journal of Endocrinology. Pharmacological profiling study characterizing ipamorelin as a selective GHS-R agonist that stimulates GH release in vitro from primary rat pituitary cells and in vivo in rodent and swine models without affecting ACTH or cortisol signaling pathways at GH-effective doses.

Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro — Histology and Histopathology. In vitro analysis of pituitary somatotroph cell populations after chronic ipamorelin exposure, reporting changes in secretory granule volume density and intracellular GH content in cultured pituitary cell models.

Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus — Journal of Pharmacology and Experimental Therapeutics. Rodent model study examining ipamorelin's effects on gastrointestinal transit pathway signaling via GHS-R1a receptor engagement; used as a tool compound to study ghrelin-receptor-mediated motility mechanisms in preclinical systems.

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV — AIDS. Analysis of tesamorelin's effects on hepatic enzyme markers in a controlled trial context, studied for its GHRH-receptor-mediated downstream signaling effects on visceral adipose tissue and hepatic metabolic pathway readouts.